Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAPDH | P04406 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471806 | 0.96 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29644745 | 0.96 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18511052 | 0.96 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18927153 | 0.96 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24878603 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL29581997 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL668595 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL26535891 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL25873876 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2258922 | 0.94 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2017075477-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\"-DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | STING1, IRF3, CGAS | TYMP 2232/4885PRMT6 4214/4885PRKAG1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.